Patents by Inventor Andrew Napper

Andrew Napper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SirT inhibitors that bind to NAD
    Patent number: 8486990
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: July 16, 2013
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Patent number: 7897765
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: March 1, 2011
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • SirT Inhibitors That Bind to NAD
    Publication number: 20090306168
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 14, 2009
    Publication date: December 10, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20090264410
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: February 9, 2009
    Publication date: October 22, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • Therapeutic compounds and uses thereof
    Patent number: 7504506
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: March 17, 2009
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
  • First stage turbine airfoil
    Publication number: 20070183897
    Abstract: The present invention provides an airfoil for a first stage turbine blade having an external surface with first and second sides. The external surface extends spanwise between a hub and a tip and streamwise between a leading edge and a trailing edge of the airfoil. The external surface includes a contour substantially defined by Table 1 as listed in the specification.
    Type: Application
    Filed: December 21, 2006
    Publication date: August 9, 2007
    Inventors: Keith Sadler, Andrew Napper
  • Substrate detection assay
    Publication number: 20060292652
    Abstract: Methods and compositions for evaluating nicotinamide-releasing activities as well as cell and organism-based evaluation methods are provided herein.
    Type: Application
    Filed: July 13, 2005
    Publication date: December 28, 2006
    Inventors: Rory Curtis, Andrew Napper, Jeffrey Hixon, Thomas McDonagh
  • Methods of treating a disorder
    Publication number: 20060074124
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: March 11, 2005
    Publication date: April 6, 2006
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Sulfonamides and uses thereof
    Publication number: 20050261332
    Abstract: Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 4, 2005
    Publication date: November 24, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Jean-Francois Pons, Russell Thomas, Manuel Navia, Thomas Coulter, Jeffrey Saunders, Bard Geesaman
  • Methods of treating a disorder
    Publication number: 20050250794
    Abstract: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I) (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: December 20, 2004
    Publication date: November 10, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh
  • Methods of treating a disorder
    Publication number: 20050209300
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: September 13, 2004
    Publication date: September 22, 2005
    Inventors: Andrew Napper, Peter Distefano, Rory Curtis, Jeffrey Hixon, Thomas McDonagh, L. Huber, Jonathan Solomon, Russell Thomas, Jean-Francois Pons
  • Therapeutic compounds and uses thereof
    Publication number: 20050187237
    Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
    Type: Application
    Filed: November 4, 2004
    Publication date: August 25, 2005
    Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel Navia, Russell Thomas, Jean-Francois Pons, Jeffrey Saunders
  • Prodrugs activated by targeted catalytic proteins
    Publication number: 20050123533
    Abstract: Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.
    Type: Application
    Filed: November 3, 2003
    Publication date: June 9, 2005
    Inventors: John Kenten, Reid Borstel, Jan Casadei, Balreddy Kamireddy, Mark Martin, Richard Massey, Andrew Napper, David Simpson, Rodger Smith, Richard Titmas, Richard Williams
  • Catalytic antibodies which hydrolyze primary amides and methods for eliciting and use of such antibodies
    Patent number: 6479265
    Abstract: Described and claimed are compounds of the formula wherein: Y is a polypeptide, R1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C1-21 alkyl, alkene, or alkyne group, R2 is a side chain of a naturally occuring amino acid, and X is Such compounds are useful as haptens and immunogens for the elicitation of antibodies which catalytically enhance the rate of formation or hydrolysis of primary amide bonds. Also described and claimed are methods employing the compounds and antibodies.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: November 12, 2002
    Assignee: Igen International, Inc.
    Inventors: Andrew Napper, Richard C. Titmas, Mark Martin, Wonpyo Hong